Beyond the core · Partners and non-dilutive funding
Beyond the core
Our capital goes to peptides and CraftMake™; these programs advance through partners or non-dilutive funding.
Ketamine ANDA payments
PharmaTher sold its FDA-approved ketamine ANDA in December 2025. Potential payments of more than US$25 million (milestones plus a 7-year profit share) depend on the purchaser's commercial performance; the first is expected in Q1 2027.
Also available to license or sell: KetaVault™ (CMC package, INDs and five orphan designations), the Phase 1-ready ketamine microneedle patch, the KetaMist® collaboration and PharmaTher's 49% interest in Sairiyo Therapeutics.
Advancing through partners or non-dilutive funding
Programs outside our core capital plan.
GAMT deficiency
3D-printed creatine for a rare childhood disease. Orphan and rare pediatric disease designation applications were submitted in October 2026; FDA decisions are expected in Q1 2027. Approval could earn a priority review voucher; recent voucher sales were US$150–200M (Abeona US$155M, Jun 2025; Jazz US$200M, Jan 2026).
Pediatrics, dysphagia, deprescribing
Telehealth programs that reuse the peptide formulation library, software and pharmacy network.
Nutraceuticals, pet health, reformulated drugs
Partner-branded products printed on the same CraftMake™ network.
Rare, psychedelic and discontinued medicines
Small-batch medicines a production line cannot serve economically.
Emergency-preparedness network
Qualified nodes print countermeasures locally; readiness contracts pursued with ASPR and DRDC.
Partner or license with us
Co-develop, license, fund or acquire any program on this page. Business development teams can request a non-confidential summary.
Partner or license with usInvestors
The corporate presentation covers each program and its potential value.
Download the deck (PDF)Forward-looking; these programs advance only as partners and funding allow. Potential ANDA payments depend on the purchaser's commercial performance and are not assured. The FDA may not grant designations, and a priority review voucher may not be awarded or sold. The emergency-preparedness network is planned and readiness contracts are prospective. The licensing or sale of assets may not occur on acceptable terms. Compounded and investigational products are not FDA-approved; KetaMist® is a trademark of its owner and is not FDA-approved. Voucher sales per company announcements: Abeona US$155M (Jun 2025), Jazz US$200M (Jan 2026). See Forward-looking statements.